Down 23% on Nov 4, and still 23% under its Nov 3 close.
−3Long-term trend
KURA's Quality Score fell 1 point on Tue, Nov 10, to -7. It closed away from its high of the day.
Follow KURA's trial news. Pro members can get an alert when Kura Oncology files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2024 high | Down 68% |
| Latest filing | 8-K, Nov 10 |
ReportToday after the close: sales of $22.8M; a loss of $0.78 a share. Kept its outlook for the year. Past reports ›
Wed Nov 4Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Sat Dec 12: American Society of Hematology…Industry event · date confirmed.
Expected to report Thu Mar 4, after the close
$519M in cash
No shelf registration or at-the-market program on file in the last three years.
Chief Operating Officer Kathleen Ford sold 10,574 shares on Sep 29, under a planned sale. 20 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
KURA is #248 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 248 |
Expected to report Thu Mar 4, after the close (in 114 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $22.8M, 10% more than a year ago; a loss of $0.78 a share, from $0.85.
“This guidance reflects non-cash accounting recognition as Kura fulfills performance obligations under its agreement with Kyowa Kirin and does not reflect the timing of cash receipts.”
KURA's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Collaboration revenue | $90M to $110M |
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 12, 2026 | +6.7% | +1.5% | +26.1% |
| May 12, 2026 | -7.3% | -2.1% | -7.4% |
| Mar 5, 2026 | -7.2% | -0.5% | +7.8% |
Sales grew every year from 2023 to 2025, to $67.5M. It lost money in each of the three years.
RSI 32.7, MACD below signal, below both averages. Not scored.
One insider bought $2.4M across 2 filings, and 4 insiders sold $1.1M across 7 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KURA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
“The development and commercialization of new products to treat cancer is intensely competitive and subject to rapid and significant technological change.”
KURA scores -7 today, which Breakaway calls Poor. It is #248 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 23% on Nov 4, and still 23% under its Nov 3 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KURA scores -7 today, which Breakaway calls Poor (below zero). That is #248 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KURA's -7.
One insider bought $2.4M across 2 filings, and 4 insiders sold $1.1M across 7 filings, in the last 6 months. The newest is Mollie Leoni, Chief Medical Officer, who sold $310K on Sep 29. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.